RTW Biotech Opportunities
| Industry | Investment trust |
|---|---|
| Founded | 2019 |
| Headquarters | London, United Kingdom |
| Website | www |
RTW Biotech Opportunities is a large British investment trust focused on investments in the biotechnology industry. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.[1]
History
Established in 2019, the company invests in companies at all stages of development from the early stages of testing to full production of pharmaceuticals.[2] Work by the administration of President Donald Trump to reach agreement with pharmaceutical companies over drug prices and tariffs, together with renewed mergers & acquisitions activity in the sector, led to renewed interest in the sector, and the company in particular, in the second half of 2025.[3][4] The company is managed by RTW Investments and the chairman is William Simpson.[5]
References
- ^ "Spectris (UK): Constituent Deletion – Update Changes in FTSE UK Index Series". FTSE Russell. 1 December 2025. Retrieved 1 December 2025.
- ^ "This trust buys shares that can double in a day or be wiped out. The risk could be worth it". The Telegraph. 19 June 2025. Retrieved 1 December 2025.
- ^ "Saba puts fresh capital into RTW Biotech's rally (and lifts Smithson stake to 16%)". Quoted Data. 5 November 2025. Retrieved 1 December 2025.
- ^ "Biotech trusts regain ground after M&A revival". Investors Chronicle. 20 October 2025. Retrieved 1 December 2025.
- ^ "RTW Biotech Opportunities NAV falls in 'volatile' period for biotech". Shares Magazine. 11 September 2025. Retrieved 1 December 2025.